SecBot SecBot
SECBOTREPLAY Home › Report › CPRX

CPRX · Catalyst Pharmaceuticals reported record financial results for Q4 and…

CATALYST PHARMACEUTICALS, INC. · 8-K filed Feb 25, 2026 at 16:23 ET

At the news

BULLISHIMPACT 8/10

8-K filed Feb 25, 2026 at 16:23 ET

Catalyst Pharmaceuticals reported record financial results for Q4 and full year 2025, with total revenues of $589.0 million (up 19.8% YoY) and GAAP net income of $214.3 million (up 30.8% YoY), driven by strong growth in FIRDAPSE and AGAMREE. The company provided 2026 revenue guidance of $615–645 million and announced favorable royalty changes for FIRDAPSE that will improve margins starting in 2026.

  • Full year 2025 total revenues were $589.0 million, up 19.8% YoY
  • GAAP net income was $214.3 million, up 30.8% YoY
  • Q4 2025 revenues were $152.6 million, up 7.6% YoY
  • FIRDAPSE net revenue grew 17.1% YoY to $358.4 million in 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access